Clipping of news on Brazilian Culture, Law and Citizenship
06/01/2015
This article was translated by an automatic translation system, and was therefore not reviewed by people.
transparent image
ANVISA has already completed the registration process of a new drug to treat hepatitis C, the Daklinza (daclatasvir). The publication will be made in the coming days. Thus, physicians and patients now have another treatment option for the disease.
The Agency also evaluates the safety and efficacy of two other active ingredients also considered innovative for the treatment of Hepatitis C: the sofosbuvir and simeprevir.
The new drug has the potential advantage over existing therapies a percentage greater efficiency, reduced treatment time and the benefits of oral use.
According to Ministry of Health, about 3% of the population may have had infection with this virus, which corresponds to 185 million people. In Brazil, the prevalence in the population is around 1.4% to 1.7%, mainly among the over-45s. According to the survey, currently 15,800 people are being treated for hepatitis C in the SUS, Brazil being one of the few developing countries in the world that provides diagnostic, testing and universal treatment for viral hepatitis, in public and free system health
virus
Hepatitis C is caused by C virus (HCV). The transmission occurs mainly through blood transfusion, sharing material for drug use, personal hygiene objects - like razors and shave, nail clippers, or other objects that stick or cut, in the manufacture of tattoo and placement piercings
Source: ANVISA
Our news are taken in full of our partner sites. For this reason, we can not change their content even in cases of typos. transparent image
This article was translated by an automatic translation system, and was therefore not reviewed by people.